Data Supplement from Cell and Molecular Determinants of <i>In Vivo</i> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Santi Suryani(Siliwangi University), Richard B. Lock(Cancer Institute of New South Wales), Anthony Letai(Dana-Farber Cancer Institute), Viktoras Frismantas, Kathryn L. Evans(Edinburgh Cancer Research), Warren Kaplan(Center for Global Development), Malcolm A. Smith(National Cancer Institute), Elise Tonna(Children's Cancer Institute Australia), Catherine A. Billups(St. Jude Children's Research Hospital), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Laura High(Children's Cancer Institute Australia), Raushan T. Kurmasheva(Unknown), Donya Moradi Manesh(Children's Cancer Institute Australia), Mark J. Cowley(Garvan Institute of Medical Research), Tríona Ní Chonghaile(Royal College of Surgeons in Ireland), Barbara Szymanska(Children's Cancer Institute Australia), Chintanu Sarmah(Children's Cancer Institute Australia), Luke Jones, Peter J. Houghton(King's College London), Hernán Carol(Children's Cancer Institute Australia), Ingrid Boehm(Children's Cancer Institute Australia), Beat Bornhäuser(University Children's Hospital Zurich)
Cited by 0
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920